Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
Sponsor: Pfizer
Terminated
Low accrual
Other terminated trials from Pfizer
Other Breast Cancer Metastatic trials with similar outcome
Listed as NCT03709082, this PHASE1/PHASE2 trial focuses on Breast Cancer Metastatic and HER2-positive Breast Cancer and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 7 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Apr 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2018 — Dec 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- University of Kansas Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .